Clinical Trials

Randomized, open-label study of oral ABL001 versus bosutinib in patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors


Study ID
Novartis CABL001A2301

NCT Number
NCT03106779 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0372

Principle Investigator
Dr. James McCloskey

Phase
III

Sponsor
Novartis


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now